Regulatory News
Thursday, December 29, 2016
BRIEF-Innocoll receives refusal to file letter from U.S. FDA for xaracoll new drug application
* Innocoll Holdings - FDA indicated xaracoll should be
characterized as drug/device combination, which would require co
submit additional information
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment